Please login to the form below
sunitinib
This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
older TKI Sutent (sunitinib) in patients with advanced RCC.
Latest news
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
-
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults.
-
BMS gains FDA approval for second Opdivo combo in kidney cancer
This approval is based on results from the phase 3 CheckMate-9ER trial, which compared Opdivo plus Cabometyx to Pfizer’s older tyrosine kinase inhibitor (TKI) Sutent (sunitinib) in patients with
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib) ... ORR. “The results for
-
BMS eyes approval for second Opdivo combo in kidney cancer
plus tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) compared to Pfizer’s older drug Sutent (sunitinib).
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
More from news
Approximately 2 fully matching, plus 74 partially matching documents found.
Latest appointments
-
Cipla appoints Novartis’ Subhanu Saxena as CEO
The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.
Cipla appoints Novartis’ Subhanu Saxena as CEO
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
-
Oncology drugs under AMNOG
Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Account Executive
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Medical Editor
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Publications Director
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
